Sarah C Akerman
Overview
Explore the profile of Sarah C Akerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roy B, Li J, Lally C, Akerman S, Sullivan M, Fratantonio J, et al.
BMC Psychiatry
. 2024 Apr;
24(1):244.
PMID: 38566055
Background: Patients with schizophrenia (SZ) or bipolar disorder (BD) may have increased risk of complications from prescribed opioids, including opioid-induced respiratory depression. We compared prescription opioid pain medication dispensing for...
2.
Mannelli P, Douaihy A, Akerman S, Legedza A, Fratantonio J, Zavod A, et al.
Am J Addict
. 2022 Feb;
31(2):142-147.
PMID: 35137481
Background And Objectives: Treatment for individuals receiving medication for opioid use disorder (MOUD) should follow an informed patient-centered approach. To better support patient autonomy in the decision-making process, clinicians should...
3.
Shulman M, Hu M, Sullivan M, Akerman S, Fratantonio J, Barbieri V, et al.
Drug Alcohol Depend
. 2022 Feb;
233:109343.
PMID: 35131528
Background: Extended-release injectable naltrexone (XR-naltrexone) is effective for treatment of patients with opioid use disorder (OUD), but initiation remains a barrier due to the challenge of tolerating opioid withdrawal prior...
4.
Mannelli P, Douaihy A, Zavod A, Legedza A, Akerman S, Sullivan M
Am J Drug Alcohol Abuse
. 2021 Nov;
47(6):753-759.
PMID: 34752714
Background: Pharmacologic treatment is recommended for many individuals with opioid use disorder (OUD). For patients who select opioid antagonist treatment, effective management of opioid withdrawal symptoms during transition to antagonist...
5.
Jain P, McKinnell K, Marino R, Vunnava P, Liles-Burden M, Desai A, et al.
Drug Saf
. 2020 Dec;
44(3):351-359.
PMID: 33258068
Introduction: After treatment with naltrexone extended-release injectable suspension (XR-NTX), a µ-opioid receptor antagonist, opioid tolerance is reduced from pretreatment baseline. Patients may be vulnerable to opioid overdose if they attempt...
6.
Kosten T, Aharonovich E, Nangia N, Zavod A, Akerman S, Lopez-Bresnahan M, et al.
Addict Behav
. 2020 Aug;
111:106538.
PMID: 32777606
Background: Opioid use disorder (OUD) is associated with cognitive dysfunction. Understanding how pharmacotherapy may affect cognition is an important treatment consideration. Methods: This was a hybrid residential-outpatient, randomized trial assessing...
7.
Nunes E, Bisaga A, Krupitsky E, Nangia N, Silverman B, Akerman S, et al.
Addiction
. 2020 Jun;
115(11):2188-2190.
PMID: 32533597
No abstract available.
8.
Comer S, Mannelli P, Alam D, Douaihy A, Nangia N, Akerman S, et al.
Am J Addict
. 2020 Apr;
29(4):313-322.
PMID: 32246728
Background And Objective: When patients seek to discontinue buprenorphine (BUP) treatment, monthly injectable extended-release naltrexone (XR-NTX) may help them avoid relapse. The efficacy of low ascending doses of oral NTX...
9.
Nunes E, Bisaga A, Krupitsky E, Nangia N, Silverman B, Akerman S, et al.
Addiction
. 2019 Jul;
115(2):239-246.
PMID: 31313402
Background And Aims: Extended-release formulations of naltrexone have emerged as effective treatment options for opioid use disorder. This post-hoc analysis examined the temporal relationship between episodes of opioid use and...
10.
Zavod A, Akerman S, Snow M, Tierney M, Sullivan M
J Am Psychiatr Nurses Assoc
. 2018 Dec;
25(4):272-279.
PMID: 30569814
The United States is experiencing an opioid epidemic. Better approaches to encourage outpatient utilization of Food and Drug Administration-approved medications for the treatment of opioid use disorder, including extended-release naltrexone...